Therefore, the developed VPAC2-selective agonists, including BAY55-9837 and DBAYL, have been inserted into chitosan-modified SeNPs (CS-SeNPs) to form BAY-CS-SeNPs and SeNPs-CTS-DBAYL, respectively, which are regarded as potential drugs for the treatment of type 2 diabetes (66, 83). Here, VIPR2 is linked to type 2 diabetes mellitus.